|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0019134,
umls-concept:C0042382,
umls-concept:C0063083,
umls-concept:C0086466,
umls-concept:C0162969,
umls-concept:C0380603,
umls-concept:C0868939,
umls-concept:C1272883,
umls-concept:C1272936,
umls-concept:C1314792,
umls-concept:C1515655,
umls-concept:C1533685
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2003-11-10
|
|
pubmed:abstractText |
Addition of various heparinoids to the lactose-introduced, water-soluble chitosan (CH-LA) aqueous solution produces an injectable chitosan/heparinoid hydrogel. In the present work, we examined the capability of the chitosan/non-anticoagulant heparin (periodate-oxidized (IO(4)-) heparin) hydrogel to immobilize fibroblast growth factor (FGF)-2, as well as the controlled release of FGF-2 molecules from the hydrogel in vitro and in vivo. The hydrogel was biodegraded in about 20 days after subcutaneous injection into the back of a mouse. When the FGF-2-incorporated hydrogel was subcutaneously injected into the back of both mice and rats, a significant neovascularization and fibrous tissue formation were induced near the injected site. These results indicate that the controlled release of biologically active FGF-2 molecules is caused by biodegradation of the hydrogel, and that subsequent induction of the vascularization occurs.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0142-9612
|
|
pubmed:author |
pubmed-author:FujitaMasanoriM,
pubmed-author:IshiharaMasayukiM,
pubmed-author:IshizukaToshiakiT,
pubmed-author:KikuchiMakotoM,
pubmed-author:MaeharaTadaakiT,
pubmed-author:MatsuiTakemiT,
pubmed-author:MorimotoYujiY,
pubmed-author:ObaraKiyohayaK,
pubmed-author:SaitoYoshioY,
pubmed-author:SimizuMasafumiM,
pubmed-author:TakaseBonpeiB,
pubmed-author:YuraHirofumiH
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
699-706
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:14607508-Animals,
pubmed-meshheading:14607508-Chitin,
pubmed-meshheading:14607508-Chitosan,
pubmed-meshheading:14607508-Coated Materials, Biocompatible,
pubmed-meshheading:14607508-Delayed-Action Preparations,
pubmed-meshheading:14607508-Endothelial Cells,
pubmed-meshheading:14607508-Female,
pubmed-meshheading:14607508-Fibroblast Growth Factor 2,
pubmed-meshheading:14607508-Heparinoids,
pubmed-meshheading:14607508-Humans,
pubmed-meshheading:14607508-Hydrogels,
pubmed-meshheading:14607508-Injections,
pubmed-meshheading:14607508-Male,
pubmed-meshheading:14607508-Materials Testing,
pubmed-meshheading:14607508-Mice,
pubmed-meshheading:14607508-Neovascularization, Physiologic,
pubmed-meshheading:14607508-Rats,
pubmed-meshheading:14607508-Rats, Sprague-Dawley
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Vascularization in vivo caused by the controlled release of fibroblast growth factor-2 from an injectable chitosan/non-anticoagulant heparin hydrogel.
|
|
pubmed:affiliation |
Department of Surgery II, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan. BXB01424@nifty.ne.jp
|
|
pubmed:publicationType |
Journal Article,
Evaluation Studies
|
